Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02718911
Title A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

Advanced Solid Tumor

Therapies

LY3022855 + Tremelimumab

Durvalumab + LY3022855

Age Groups: adult
Covered Countries USA | BEL

Facility Status City State Zip Country Details
Sarah Cannon Research Institute at HealthOne Denver Colorado 80218 United States Details
Florida Cancer Specialists Sarasota Florida 34232 United States Details
Winship Cancer Center Emory University Atlanta Georgia 30322 United States Details
New York University Medical Center New York New York 10016 United States Details
Columbia University College of Phys & Surgeons New York New York 10032 United States Details
Sarah Cannon Cancer Center Nashville Tennessee 37203 United States Details
Tennessee Oncology PLLC Nashville Tennessee 37203 United States Details
Universitair Ziekenhuis Antwerpen Edegem 2650 Belgium Details
Universitair Ziekenhuis Gent Gent 9000 Belgium Details
GZA St Augustinus Wilrijk 2610 Belgium Details
Masarykuv Onkology Institute Brno Czech Republic 656 53 Czechia Details
Rambam Medical Center Haifa 3109601 Israel Details
Hadassah Medical Center Jerusalem 9112001 Israel Details
Sheba Medical Center Ramat Gan 5262000 Israel Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field